S-1: Bolt Projects Holdings Files for Resale of Up to 9.8 Million Shares

Bolt Projects Holdings intends to register for resale up to 9.8 million shares of its common stock by a selling stockholder.

Summary

• Bolt Projects Holdings has filed a registration statement for the resale of up to 9,856,859 shares of its common stock.
• The shares are to be resold by Triton Funds LP, the selling stockholder.
• These shares include up to 6,856,859 shares issuable under a common stock purchase agreement and up to 3,000,000 shares underlying a warrant.
• Under the purchase agreement, Bolt can require Triton to purchase up to $1,500,000 of common stock between the effective date of the registration statement and June 30, 2025.
• The purchase price per share will be 75% of the lowest daily VWAP during the ten trading days prior to payment.
• Triton also holds a warrant to purchase up to 3,000,000 shares at an exercise price of $0.50 per share, exercisable beginning August 13, 2025, and expiring on August 13, 2030.
• Bolt will bear the costs of registering the shares, while Triton will bear commissions and discounts from its sales.
• Bolt's common stock is listed on The Nasdaq Global Market under the symbol BSLK.
• The company has received notice of deficiencies with Nasdaq's continued listing requirements and risks delisting.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there's potential for future revenue and capital, the company faces significant financial challenges, including a history of losses, debt obligations, and Nasdaq listing deficiencies. The reliance on a single product and manufacturing partner also adds risk.

Positives

• The purchase agreement provides Bolt with a potential source of capital of up to $1,500,000.
• The warrant held by Triton could bring in additional capital to Bolt if exercised.
• The company is an emerging growth company and smaller reporting company, allowing for reduced reporting requirements.

Negatives

• The sale of securities being offered in this prospectus could result in adverse effects on the market for our common stock, including increasing volatility, limiting the availability of an active market, or resulting in a significant decline in the public trading price of our common stock.
• The company has a history of net losses and an accumulated deficit of $455.5 million as of September 30, 2024.
• The company has received notice of deficiencies with Nasdaq's continued listing requirements and risks delisting.

Risks

• Sales of a substantial number of securities in the public market by the Selling Stockholder or by our other existing securityholders could cause the price of our common stock and Warrants to fall.
• The company may not be able to achieve or maintain profitability in the future.
• The company's failure to meet Nasdaq's continued listing requirements could result in a delisting of its common stock.
• The company's operating results may fluctuate significantly due to factors outside of its control.
• The company may be unable to adequately control its expenses or raise additional capital on favorable terms.
• The company may not be able to generate sufficient cash to service all of its debt obligations.
• The company's revenue is primarily generated from sales of its b-silk product, making it highly dependent on the success of this product.
• b-silk and future biomaterial product candidates may not achieve market success.
• The company may be unable to manage growth effectively.
• The company currently relies on a single manufacturing partner and manufacturing facility for the production of b-silk.
• The company has limited experience in marketing and selling b-silk.
• The company may not be able to protect adequately its patents and other intellectual property assets.
• Government regulations and private party actions relating to the marketing and advertising of cosmetic products that include b-silk or other products we develop may restrict, inhibit or delay our ability to sell such products and harm our business.

Future Outlook

The company plans to use proceeds from the sale of shares to Triton and the exercise of the Triton Warrant for general corporate purposes and working capital.

Industry Context

The document mentions the global silicone market is estimated to be between $16.7 billion and $19.9 billion, with the silicone elastomers subsector representing a $6.3 billion to $10.0 billion global market. The document positions b-silk as a sustainable alternative to silicone elastomers in the beauty industry.

Comparison to Industry Standards

• The document mentions several competitors in the biomaterials space, including Givaudan Active Beauty, Spiber Inc., Seevix Material Sciences, and Evolved by Nature.
• It highlights that b-silk has been on the market since 2019, suggesting a more advanced stage of commercialization compared to some competitors.
• The document presents data from claim studies and consumer panels comparing b-silk to silicone elastomers and other materials, suggesting a focus on demonstrating comparable or superior performance.

Related Party Transactions

• The document mentions a common stock purchase agreement with Triton Funds LP, the selling stockholder.
• The document mentions a settlement agreement with Golden Arrow Sponsor LLC regarding the excise tax liability and the exchange of private placement warrants.
• The document mentions that the Sponsor, or its permitted transferees, have the option to exercise the Private Placement Warrants on a cashless basis and the Sponsor or its permitted transferees will also have certain registration rights related to the Private Placement Warrants (including the shares of common stock issuable upon exercise of the Private Placement Warrants).

Stakeholder Impact

• Shareholders may experience dilution from the sale of shares to Triton and the exercise of the Triton Warrant.
• Shareholders may see the price of their common stock fall due to sales by the Selling Stockholder or other existing securityholders.
• Shareholders may be negatively impacted if the company is delisted from Nasdaq.
• Stakeholders may be negatively impacted if the company is unable to continue as a going concern.

Next Steps

• The Selling Stockholder will determine when and how it sells the shares offered in this prospectus as described in the Plan of Distribution.
• The company intends to use the proceeds that it receives from Tritons purchases under the Purchase Agreement and the exercise of the Triton Warrant for general corporate purposes and its working capital requirements.
• The company may seek additional capital in the private and public equity or debt markets.
• The company intends to cure the deficiencies with Nasdaq's continued listing requirements.

Key Dates

Keywords

common stock, resale, warrant, Triton Funds LP, Bolt Projects Holdings, BSLK, registration statement, purchase agreement, securities